Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
51 hedge funds and large institutions have $23.8M invested in Clearside Biomedical in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 12 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
157% more capital invested
Capital invested by funds: $9.23M → $23.8M (+$14.5M)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
11% more funds holding
Funds holding: 46 → 51 (+5)
0.54% more ownership
Funds ownership: 0.84% → 1.39% (+0.54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.68M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$3.73M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$452K |
| 4 |
Jane Street
New York
|
+$254K |
| 5 |
Millennium Management
New York
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$195K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$129K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$65.2K |
| 4 |
N
Natixis
Paris,
France
|
-$55.6K |
| 5 |
Bank of New York Mellon
New York
|
-$34.5K |
CLSD Hedge Fund Activity: Q1 2024 in Review
51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2024, worth a combined $23.8M — up 157% from $9.23M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CLSD positions and 12 closed out — a net gain of 5 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.68M. The largest seller was Morgan Stanley, cutting an estimated $195K.
- 51 institutional investors held Clearside Biomedical (CLSD) as of Q1 2024, up from 46 in Q4 2023.
- Funds reported $23.8M of Clearside Biomedical stock for Q1 2024, up 157% quarter-over-quarter.
- 17 funds opened new Clearside Biomedical positions in Q1 2024 and 12 closed out, a net change of +5 holders.
- The largest Clearside Biomedical buyer in Q1 2024 was Armistice Capital, an estimated $5.68M added.
- The largest Clearside Biomedical seller in Q1 2024 was Morgan Stanley, an estimated $195K sold.
Based on aggregated 13F filings for Q1 2024.